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Sir,
Carcinogen-induced tumours in intact mice exhibit a substantial
enrichment of CD4
þFOXP3
þ regulatory T cells (Tregs) (Betts
et al, 2007) and many forms of malignant disease are associated
with an expansion of circulating Tregs in patients (reviewed in
Betts et al, 2006). Galon et al (2006) demonstrated recently that the
type, density and location of T cells within colorectal tumours
predicted clinical outcome. In contrast, Tregs have been shown to
increase with progression of malignant disease and to correlate
negatively with prognosis (Curiel et al, 2004; Wolf et al, 2005).
Definitive studies need to be performed to establish the relative
contribution of the accumulation of Tregs among tumour-
infiltrating lymphocytes to prognosis since it is currently unclear
if an early accumulation of Tregs into the tumour environment
allows disease progression. Future studies should include a
retrospective analysis of Treg infiltration of tumours removed
from patients to establish whether patients with early disease and a
relatively large infiltration of Tregs had a worse prognosis than
predicted by conventional histopathological scoring and conver-
sely, whether those with advanced disease but a relatively low
infiltration of Treg had a better prognosis than predicted.
Evidence collected from mice suggests that depletion of Tregs
enhances immunosurveillance of tumours and uncovers new
responses to tumour antigens in patients (Curiel et al, 2004;
Clarke et al, 2006). Hence, removal of Tregs may represent a
component of future strategies to trigger immune-mediated
elimination of tumour tissue. Nishikawa et al (2003) demonstrated
that vaccination with self-antigen expanded Treg with enhanced
FOXP3 expression and suppressive capacity. This highlights the
importance of co-depleting Treg not only to boost tumour-specific
immune responses but also to suppress expansion of Treg with
shared antigen specificity.
The optimal vaccination/depletion strategy needs to be estab-
lished by defining the impact of preoperative chemotherapy and
surgery on the development of antitumour immune responses.
Surgical removal of malignant disease is likely to remove the bulk
of Treg TIL and reduce the production of suppressive signalling
networks, which would undoubtedly improve the likelihood of
successful antitumour immune responses to clear residual
malignant cells. However, the impact of major surgery on the
capacity of the immune response needs to be established. It is also
important to weigh up the benefit of postoperative immuno-
therapy and adjuvant chemotherapy. Chemo/radiotherapy might
reduce the capacity of the immune system to mount antitumour
immunity. In light of conflicting reports describing the ability of
certain treatments to deplete Treg efficiently (Attia et al, 2005;
Dannull et al, 2005), conventional chemotherapeutic drugs that are
proven to deplete Treg might be the best starting point to develop
strategies to co-vaccinate and deplete Treg. Tregs have been shown
to be highly susceptible to cyclophosphamide (Ghiringhelli et al,
2004) and fludaribine (Beyer et al, 2005) and previous work by
North (1982) has indicated that vaccination with tumour antigens
might go hand-in-hand with chemotherapy to deplete Treg and
promote antitumour immunity.
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